SINGAPORE-- One of the world's most prestigious medical journals called for India to abandon its current proposal to change the way it regulates drugs and come up with a new plan.
SINGAPORE-- China sales of Sanofi's heart and diabetes drugs contributed heavily to sales growth in the country last year, with the market witnessing twice the growth of the rest of the world combined.
SINGAPORE-- Aurobindo Pharma's U.S. unit, AuroMedics Pharma USA, says that if the U.S. FDA manages to speed up its approval process for generic drugs in the coming fiscal year, its earnings could shoot up by half.
Amid rapid growth in China's medical device sector, investors are looking to cash in on the market with a string of M&A deals.
Cipla, which has been building beachheads and production capacity in hot spots where most Western drugmakers are loath to go, will now create a joint venture in Morocco and build a drug manufacturing facility there.
South Korea's Celltrion will start sales of Remsima, its biosimilar of Johnson & Johnson's Remicade (infliximab) in a dozen European countries in February, according to Joon Seok Kim of Celltrion Public Relations on Tuesday.
SINGAPORE-- Cellular Biomedicine Group has bought chimeric antigen receptor T cell therapies from the Chinese PLA General Hospital in a deal valued at RMB12 million ($1.9 million) to be paid in three installments.
SINGAPORE-- A proposed $200 million merger between India's Strides Arcolab and Shasun Pharmaceuticals is about to be tested by Shasun's shareholders.
FiercePharma brings you notes on the Asian and emerging markets operations of major drug companies from fourth-quarter earnings calls to explain what C-suite executives are focused on.
SINGAPORE-- The head of Guinea's Ebola-response program wasted no time in announcing approval of broader use of Fujifilm's Avigan (favipiravir) influenza drug for treating early cases of Ebola in the West Africa nation.